FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis

Table 4 Characteristics of seven non-invasive models in the subgroup population

Non-invasive models	Subgroup population (n = 117)	High-risk MASH group (n = 52)	Non-high-risk MASH group (n = 65)	P value
FAST	0.5 (0.3, 0.7)	0.6 (0.5, 0.8)	0.3 (0.2, 0.5)	< 0.05
FIB-4	1.0 (0.6, 1.6)	1.4 (0.9, 2.6)	0.7 (0.5, 1.2)	< 0.05
APRI	0.5 (0.3, 1.0)	0.7 (0.5, 1.2)	0.4 (0.2, 0.7)	< 0.05
Forns index	4.4 ± 1.9	5.1 ± 1.9	3.9 ± 1.7	< 0.05
ARR	0.6 (0.5, 0.8)	0.7 (0.5, 0.9)	0.5 (0.4, 0.7)	< 0.05
S index	0.1 (0.1, 0.2)	0.2 (0.1, 0.3)	0.1 (0.1, 0.2)	0.51
GPR	0.7 (0.5, 1.2)	0.7 (0.5, 1.2)	0.7 (0.4, 1.2)	0.81

MASH: Metabolic dysfunction-associated steatohepatitis; FAST: FibroScan-aspartate transaminase; FIB-4: Fibrosis-4; APRI: Aspartate transaminase to platelet ratio index; ARR: Aspartate transaminase to alanine transaminase ratio; GPR: Gamma-glutamyl transpeptidase to platelet ratio.